Verónica Mingrone (she/her/hers)

M.D., Infectious Diseases Specialist, Master in Clinical Research
Fundación IDEAA, Argentina

Education:

MASTERS IN CLINICAL RESEARCH| 2019-2021| IUHIBA, BUENOS AIRES, ARGENTINA.
INFECTIOUS DISEASES SPECIALIST| 2017| BUENOS AIRES UNIVERSITY (U.B.A.)
•GPA: 10
INFECTIOUS DISEASES SPECIALIST RESIDENCY| 2012-2017| F. J. MUÑIZ INFECTIOUS DISEASES HOSPITAL, BUENOS AIRES, ARGENTINA
MEDICAL DOCTOR (M.D.)| 2011| SCHOOL OF MEDICINE, BUENOS AIRES UNIVERSITY (UBA), BUENOS AIRES, ARGENTINA.
•GPA: 8.24.
PROJECT MANAGEMENT EXPERT COURSE| 2023| NATIONAL TECHNOLOGICAL UNIVERSITY (UTN), BUENOS AIRES, ARGENTINA.
GOOD CLINICAL PACTICE (G.C.P.)| 2020| NIDA CLINICAL TRIALS NETWORK.
CLINICAL TRIAL INVESTIGATOR COURSE AND GCP TRAINING, FEFYM| 2013| BUENOS AIRES, ARGENTINA.
ENGLISH | IELTS| 2022-ONGOING| PRIVATE LESSONS, BUENOS AIRES, ARGENTINA. LEVEL: ADVANCED.

Experience

MASTERS´ TEACHER AND TUTOR, MASTER IN CLINICAL RESEARCH| UNIVERSITY
INSTITUTE OF ITALIAN HOSPITAL OF BUENOS AIRES (IUHIBA), BUENOS AIRES, ARGENTINA|
2023-ONGOING.

MASTERS´ TEACHER AND TUTOR, MASTER IN MEDICAL INFORMATICS| 2023|
UNIVERSITY INSTITUTE OF ITALIAN HOSPITAL OF BUENOS AIRES (IUHIBA), BUENOS AIRES,
ARGENTINA| 2023-ONGOING.

INFECTIUOS DISEASES SPECIALIST, OUTPATIENT CARE UNIT| F. J. INFECTIOUS DISEASES
HOSPITAL, BUENOS AIRES ARGENTINA| 2020-ONGOING.
INFECTIOUS DISEASES SPECIALIST (OUTPATIENT CARE)| IDEAA FOUNDATION, BUENOS AIRES, ARGENTINA| 2017-ONGOING.

CLINICAL TRIAL INVESTIGATOR| IDEAA FOUNDATION, BUENOS AIRES, ARGENTINA| 2013-ONGOING

INFECTIOUS DISEASES SPECIALIST (VISITANT), OUTPATIENT CARE UNIT | 2018| CLINIC BARCELONA HOSPITAL, BARCELONA, SPAIN.
INFECTIOUS DISEASES SPECIALIST, EMERGENCY DEPARTMENT| F.J. MUÑIZ INFECTIOUS DISEASES HOSPITAL, BUENOS AIRES, ARGENTINA| 2012-2017.
MEMBER OF ARGENTINIAN INFECTOLOGY ASSOCIATION (SADI)-HIV/ITS COMITEE| 2018-ONGOING.

Clinical Trial Experience

 D2ARLING Study (IIS): Phase IV (2020-Actualidad). Subinvestigator.

 ViiVGSK212483 (DYNAMIC): Phase IIb (2022). Subinvestigator.

 ViiVGSK208379 (DOMINO): Phase IIb (2021-Ongoing). Subinvestigator

 MK-8591A-020: Fase IIb (2021-Actualidad). Subinvestigator.

 DARURIF Study (Cecchini-SADI Scholarship 2018-2019). Principal Investigator.

 Viiv/GSK205888 (BRIGHTE): Phase III (2016-Ongoing). Subinvestigator.

 Viiv/GSK207966 (ATLAS2M): Phase III (2017-Ongoing). Subinvestigator.

 Viiv/GSK205888 (ATLAS): Phase III (2016-Ongoing). Subinvestigator.

 Viiv/GSK117172 (ARIA): Phase III (2014-2020). Subinvestigator.

 Viiv/GSK205543 (GEMINI): Phase III (2018-2020). Subinvestigator.

 START (Strategic Timing of Antiretroviral Treatment): Phase IV (2012-2021). Subinvestigator.

Poster(s):

• (1590) Resistance to Etravirine, Doravine and Rilpivirine in People Living with HIV Experiencing Virologic Failure to a First-line Antiretroviral Regimen Based on a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in a Latin American Country.
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET